Determination of the role of calcium on instability of neurotoxic metabolite of ecstasy by HPTLC-mass by Bardia Jamali et al.
Jamali et al. DARU Journal of Pharmaceutical Sciences 2013, 21:9
http://www.darujps.com/content/21/1/9RESEARCH ARTICLE Open AccessDetermination of the role of calcium on
instability of neurotoxic metabolite of ecstasy
by HPTLC-mass
Bardia Jamali1, Yalda Hosseinzadeh Ardakani1, Mohammad-Reza Rouini1, Alireza Foroumadi2, Salimeh Amidi3,
Vahid Hossein Zadeh Aghdam4 and Farzad Kobarfard3*Abstract
Background: Ecstasy is one of the popular illicit drugs in the world and its usage has been recently increased in
Iran. This compound can destroy the serotonergic neurons and produces cognitive and psychopathology diseases.
3,4-dihydroxymethamphetamine (HHMA) which is the main metabolite of this compound, seems to be responsible
for this effect. However, no consensus has been reached among the researchers about its role. This disagreement
between the researches may be due to failure in determination of HHMA as free form in physiological fluids. In this
study, the stability of this crucial metabolite of ecstasy was examined in different mediums.
Methods: The stability of HHMA was studied in the perfusion medium and water at 100 and 10 ng/mL
concentrations. Moreover, the effect of temperature (0–25°C), pH (3–10), calcium chloride (0–150 g/L) and
ethylenediaminetetraacetic acid (EDTA) on the stability of HHMA was also examined.
Results: Our result suggested that the free form of HHMA could be degraded in the perfusion medium. The rate of
this degradation has direct proportion to temperature (at 25°C = 0.037 min-1 and at 0°C = 0.002 min-1). Calcium
chloride and sodium bicarbonate are two responsible components in this instability. Moreover, the alkaline pHs and
increasing the shaking time can accelerate this effect. Although, while degradation was prevented at pH=3, EDTA
could only reduce this rate about 30%.
Conclusions: Calcium cation can act as an accelerator of HHMA degradation. Therefore, the perfusion medium
should not contain Ca2+ and the pH of medium is better to be adjusted at acidic range. Since, the internal cellular
source of calcium is endoplasmic reticulum system, it can be assumed that, this cation may change HHMA and
dopamine to reactive compounds that can bind covalently to the cysteinyl group of biological compounds and
damage cellular components.
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Ecstasy (3,4-methylenedioxymethamphetamine, MDMA)
is one of the popular drugs of abuse among youths. The
tendency toward this compound has increased since the
last two decades [1,2]. In 2009, it was reported that 2.8
million of Americans over 12 years old have abused
MDMA at least once [3]. The usage of this compound* Correspondence: kobarfard@sbmu.ac.ir
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reproduction in any medium, provided the orhas been recently increased among Iranian youths as
well [4,5].
MDMA is a releaser and reuptake inhibitor of sero-
tonin and dopamine which can destroy serotonin axon
terminal of brain and produces cognitive dysfunction
and psychopathology diseases in humans. However, the
mechanism behind this phenomenon is not clearly
known [2,6,7]. It was reported that the intracranial ad-
ministration of MDMA in animals does not produce any
neurotoxic effects. However, the peripheral administra-
tion can do so [7]. This result and some other reportstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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neurotoxic activity [7,8].
MDMA is metabolized via either O-demethylation or
N-dealkylation in humans and rats. N-dealkylation path-
ways produce 3,4-methylenedioxyamphetamine (MDA)
which is known as “Love drug” and has similar pharmaco-
logical effects to MDMA [1]. O-demethylation produces
reactive catechol metabolite, i.e. 3,4-dihydroxymetham-
phetamine (HHMA) (Figure 1). HHMA is the main me-
tabolite of MDMA in urine and plasma which exist in
conjugated form (sulfate and glutathione) and there is no
report for determination of its free form in biological
fluids [2,7]. It has been reported that HHMA conjugated
with glutathione could produce apoptosis on rat hipocam-
pal neurons [8].
Over the years, different reports have been published
about the neurotoxicity associated with MDMA metabo-
lites. Some reports proposed that MDA is responsible
for such an effect [6] and the others have introduced
HHMA and thioether adducts as the toxic metabolite
which cause apoptosis and damage in the cells [7,8].
This controversy may be due to the failure in determin-
ation of HHMA as a free form in brain after MDMA
administration.
HHMA, due to its catecholamine structure, can dis-
play various properties. The catecholamine moiety is
prone to oxidation and formation of ortho quinone-like
structure. Oxidizing agents such as ClO-, MnO4
- and
etc., alkaline pHs and light can trigger this reaction [9].
Moreover, MDA can also be O-demethylated and form
another metabolite with catecholamine structure which
can exert similar properties with HHMA [2]. To the best
of our knowledge, there are no reports about HHMA
stability in physiological fluids and there are only some
reports regarding the stability of dopamine which has
the closest structure to HHMA. These reports indicate
that dopamine, in the presence of oxidizing agents likeFigure 1 Structure of MDMA and its metabolites.Mn3+ or NaIO4, is converted to the reactive compounds
such as aminochrome (AC), indole-5,6-quinone and 5,6-
dihydroxyindole. These reactive compounds can bind
covalently to the cysteinyl group of biological com-
pounds in the body and damage cellular components
such as DNA, proteins and lipids. The role of these re-
active compounds in Alzheimer’s and Parkinson’s has
been established (Figure 2) [10,11].
Due to the ethical and safety issues, studying the me-
tabolism changes of illicit or toxic compounds at high
concentration in human subjects is constrained. There-
fore, the kinetic of these compounds is preferred to be
studied in similar systems to human such as isolated ani-
mal organs. In these cases, the perfusion medium is used
instead of plasma [12]. However, the stability of the
compounds and their related metabolites in the perfu-
sion medium is of important concern. Since MDMA is
an illicit compound and can cause multi organ failure,
especially liver damage and death at high concentrations
[13], its metabolic transformation is preferred to be
studied in intact animals or in in vitro perfused organs.
In the present study, stability of HHMA in perfusion
medium was examined. The constituents of this medium
appear in almost all of physiological fluids of human
body. Determination of the possible effect of these con-
stituents on the stability of HHMA free form could help




Ultrapure water was obtained from Millipore Direct-Q
system (France). HHMA was synthesized in four steps,
from commercially available 3,4-dimethoxy-benzalde-
hyde and nitroethane, through procedures previously
reported [8]. Dopamine was a gift from Caspian Tamin
Pharmaceutical Company. HPLC (high performance
Figure 2 The oxidation pathway of dopamine [10].
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micals of analytical grade were purchased from Merck
(Darmstadt, Germany). The Krebs buffer (6.903 g/L NaCl,
0.335 g/L KCl, 0.162 g/L KH2PO4, 0.163 g/L MgSO4,
0.305 g/L CaCl2, 2.1 g/L NaHCO3 and 1 g/L glucose, pH
was adjusted to 7.2-7.4) was used as a perfusion medium.
Apparatuses and chromatographic conditions
The Knauer chromatographic system which was used,
consisted of a pump model K-1001, a fluorescence de-
tector (FL) model RF-10AXL, a photodiode array (PDA)
detector model K-2800, a solvent degasser and a 100 μl
loop injector. EZChrom Elite software was used for in-
strument control, data acquisition and analysis. The
separation of analytes was performed at ambient
temperature (25°C) on the ChromolithW Performance
RP-18e (100 × 4.6 mm) column with ChromolithW RP-18e
(5 × 4.6 mm) guard from Merck (Darmstadt, Germany).
The FL detector wavelength was fixed at 285 nm for ex-
citation and at 320 nm for emission and PDA wave-
length was fixed at 285 nm. The mobile phase was 0.02
M potassium dihydrogen phosphate (KH2PO4) solutionwith pH = 3 (orthophosphoric acid was used for pH
adjustment).
The Cecil UV spectrophotometer model CE9500 and
Camag high performance thin layer chromatographic
(HPTLC) system consisted of a Camag TLC Scanner 3,
a TLC automatic developing chamber and a Camag
automatic TLC Sampler 4 with a PDA and FL detectors,
were used. In the HPTLC system, the separation was
performed on HPTLC plates coated with silicagel 60
F254 (10 × 10 cm) from Merck (Darmstadt, Germany).
A mixture of dioxane:methanol:chloroform:acid acetic
(6:1:1:1,v/v/v/v) was used as the mobile phase. The in-
strument was controlled and the data were analyzed by
winCATS planar chromatography manager software.
TLC plates developed by HPTLC were subjected for
TLC-Mass spectrometry using a 1200 Agilent HPLC
pump coupled to a Agilent electrospray ionization (ESI)
mass detector (6410 Triple Quadrupole) through a
Camag TLC-MS interface. Methanol was used for elu-
tion of TLC spots to the mass detector. The mass de-
tector was operated in positive mode (ESI+) and the
fragmentor voltage was 60 V. Detection was performed
in full scan mode.
Stability study
The stability of five replicate samples of HHMA at
concentrations of 100 and 10 ng/mL, at ambient
temperature (25°C) and 0°C, in both perfusion medium
and water was examined for 24 hours. In the case of per-
fusion medium, the stability was checked at 0, 5, 15, 30,
60, 120 and 180 min, and in the case of water, samples
were taken at 0, 5, 15, 30, 60, 120, 180, 240 min and 24
hours. These samples were analyzed by the HPLC/FL for
the determination of HHMA residual in corresponding
medium.
The impact of perfusion medium components on
HHMA stability was examined separately on 5 replicate
samples (at a concentration appeared in perfusion
medium) of the 100 ng/mL aqueous solution of HHMA.
Samples were analyzed immediately after dissolving the
component by the HPLC/FL and were compared with
the 100 ng/mL freshly prepared samples of HHMA in
water. The influence of pH (3–10) and different concen-
tration (up to saturated concentration) of ethylenediami-
netetraacetic acid (EDTA) on the stability of HHMA in
perfusion medium was also investigated.
Moreover, the stability of HHMA in water in the pres-
ence of calcium chloride (CaCl2) (concentration 0–150
g/L) was studied. Samples were analyzed by HPLC/UV
immediately after the changes were made and the results
were compared with the results obtained for freshly pre-
pared samples of HHMA in corresponding medium.
This part was done on 5 replicate samples of 1 μg/mL
solution of HHMA.
Figure 3 The degradation rate of 100 ng/mL solution of HHMA in perfusion medium at ambient temperature and 0°C. Points shown as
mean ± SD, n=5.
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HHMA aqueous solution (1 μg/mL) was also examined
by HPTLC system on 3 replicate samples.
In another part of the present study, those compo-
nents which were supposed to be responsible for in-
stability of HHMA in perfusion medium were also
examined, for their impact on the stability of dopamine
(1 μg/mL aqueous solutions).
Statistics
The t-independent test was used for determination of
differences between means of groups (P < 0.05).
Results and discussion
The 100 and 10 ng/mL solutions of HHMA in water
were stable at ambient temperature and 0°C for 24
hours. No significant differences between area under the
curve (AUC) of peak of freshly prepared samples and
tests were observed (n = 5, P > 0.05), whereas the 100
and 10 ng/mL solutions of HHMA in perfusion mediumFigure 4 The effect of pH on degradation of HHMA (1 μg/mL) in wate
pH=9; a2: changing the pH of alkaline sample to 3; a3: at pH=3; b1: at pH=
pH=7.3.were unstable. After 2 hours, about 100% of the 100 ng/mL
solution of HHMA was degraded at ambient temperature
(Kdegradation = 0.037 min
-1 (0.030-0.047) at 25°C) and a new
small peak appeared in the HPLC/FL chromatogram. Re-
duction of the temperature to 0°C could reduce the rate of
degradation, so that after 2 hours, only about 20% of the
100 ng/mL solution of HHMA was degraded (Kdegradation =
0.002 min-1 (0.0006-0.003) at 0°C) (Figure 3). In the case of
10 ng/mL solution of HHMA in perfusion medium, the
similar pattern was observed.
While the reduction of pH to 3 could stop the degrad-
ation reaction, increasing the pH could accelerate deg-
radation rate, in such a way that the corresponding peak
to HHMA in HPLC/FL or HPLC/UV chromatograms
disappeared rapidly after pH was reached to 9. The
HHMA peak disappearance was permanent and by redu-
cing the pH of the alkaline samples to 3, the HHMA
peak did not appear again (Figure 4).
Our results were in accordance with Gouarne et al. re-
port [14]. They reported that the degradation rate ofr (a) and perfusion medium (b) at ambient temperature. a1: at
9; b2: changing the pH of alkaline sample to 3; b3: at pH=3; b4: at
Figure 5 The HPTLC chromatogram of HHMA (1 μg/mL) in
water and in the presence of CaCl2 (150 g/L).
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The hydroxyl groups in the catecholamine structure
deprotonate easier at pHs higher than 3 and form the cor-
responding quinone structure readily. At high pHs, quin-
ine structures are susceptible to oxidation, cyclization and
polymerization [10,11]. It should be mentioned that the
pH of aqueous solutions of HHMA was about 3 and per-
haps due to this reason, HHMA has been stable in these
aqueous solutions.
Adding EDTA to the HHMA solution in perfusion
medium, even at a saturated concentration could only
reduce the rate of degradation about 30%. It has been
reported that MgCl2 and CaCl2 enhances the oxidation
of ascorbate [15]. EDTA, due to its chelating property,
can reduce the rate of oxidation reaction by sequestering
the Ca2+ and Mg2+, but this chelator was not effective in
inhibition of HHMA peak reduction.
In order to further investigate this phenomenon, the
components of perfusion medium (at their concentra-
tions in perfusion medium) were added to HHMAFigure 6 Extracted ion chromatogram at (m/z 182) of HHMA (1 μg/mLaqueous solution separately. Adding MgSO4, NaCl, KCl,
KH2PO4 or glucose did not affect the AUC of HHMA
peak even after 2 hours. These results indicated that Mg2+,
which is a crucial cation in Catechol-O-methyltransferase
(COMT, an enzymes that play a role in catecholamine deg-
radation) activity [16] and can bind to hydroxyl ring of cat-
echolamine at pHs higher than 7 [17], has no effect on
HHMA instability. However, CaCl2 and NaHCO3 were the
components which caused HHMA concentration to re-
duce. In case of NaHCO3, the reduction of HHMA con-
centration was expected due to its ability in increasing the
pH of solutions. However, the observed rate for concentra-
tion reduction of HHMA, was slower than the observed
rate for HHMA in perfusion medium. In addition to
NaHCO3, CaCl2 could cause reduction in concentration of
HHMA in aqueous solution. When the concentration of
CaCl2 increased from 0.3 to 150 g/L, the AUC of HHMA
peak reduced faster. Moreover, increasing the shaking time
from 5 to 60 seconds reduced the AUC of HHMA peak,
significantly.
The HPTLC analysis of HHMA aqueous solution in
the presence of CaCl2 showed that a new spot appeared
in the chromatogram after adding CaCl2 (150 g/L) with
the Rf = 0.25. This spot did not exist in the chromato-
grams of HHMA or CaCl2 aqueous solutions alone.
Mass spectroscopic analysis of this spot on a triple quad-
ruple mass detector revealed that its molecular weight is
different from that of HHMA. Moreover, the UV
spectrum of this spot was different from the UV
spectrum of HHMA aqueous solution (Figures 5 and 6).
The same results were obtained in all replication. These
results indicated that HHMA has changed to other) in the absence (a) and in the presence (b) of CaCl2 (150 g/L).
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reports in the literature about a direct role of CaCl2 in
oxidation of catecolamines. It seems that Cl- has no
impact on stability of HHMA, because adding NaCl
could not reduce the AUC of HHMA peak over 2
hours. It could be speculated that calcium cation (Ca2+),
due to free d-orbital in its electronic configuration,
can act as a catalyst or something like that in this
phenomenon, but magnesium cation (Mg2+), due to
the lack of this free d-orbital, cannot play such role.
It has been reported that HHMA can be oxidized to
related ortho quinone compounds that react with nu-
cleophilic groups of macromolecules or form neurotox-
ins [8,18]. Moreover, HHMA can change to carbene
intermediate and covalently bind to heme iron of
CYP2D6 in the biological systems [18,19]. Beside
HHMA, dopamine, which is structurally the most simi-
lar compound to HHMA, is oxidized in the presence of
MnO2 and NaIO4 to the reactive ortho quinone com-
pounds which covalently bind to cysteinyl group of pro-
teins and impair their functions. Moreover, reactive
ortho quinone compounds are responsible for neurode-
generative process of dopaminergic system. When the
oxidizing agents were added to the aqueous solutions of
dopamine, the absorption intensity at λ = 280 nm
decreased and two new peaks appeared at λ = 300 and
475 nm in the UV spectrum, which were associated with
AC structure [10,11]. The similar pattern changes were
reported in the UV spectrum of HHMA when oxidized
electrochemicaly [8]. In our study, such a phenomenon
was observed when the CaCl2 was added to aqueous so-
lution of dopamine. In the UV spectrum when CaCl2
(150 g/L) was added to 1 μg/mL dopamine aqueous so-
lution, the intensity of the absorption at λ = 276 nm
decreased, and after 10 min a new peak at λ = 294 and a
small peak at about 455 nm appeared.
In light of the above observations, it could be specu-
lated that HHMA, in the presence of CaCl2, is oxidized
to its corresponding aminochrome like structures.
Therefore, in study of MDMA effect on isolated organs,
the perfusion medium should not contain CaCl2 or Ca
2+.
However, calcium cation has a crucial role in cell bio-
logical activity, vesicle movement and exocytosis [20]. The
total vesicular concentration of Ca2+ is about 1.6 g/L and
the main internal source of this cation is endoplasmic
reticulum. In addition to, CYP450 isoenzymes are located
and activated in endoplasmic reticulum. Therefore, the
role of this cation in generating reactive ortho quinonic
compounds and neurotoxicity associated with MDMA
could be speculated.
Conclusion
Serotonin neuron damage which is related to the
MDMA metabolites is one of crucial aspect of MDMAside effects. Different reports have been published about
this effect, some of them suggesting HHMA as the
neurotoxic metabolite of MDMA, while other reports
suggest MDA as the neurotoxin. One of the possible rea-
sons for this controversy can be due to failure in HHMA
determination as a free form in these studies.
The results of our study indicated that Ca2+ besides
sodium bicarbonate can be responsible components in
HHMA concentration reduction in perfusion medium.
In order to obtain reliable results in these cases, the per-
fusion medium should not contain Ca2+ and the pH of
medium is better to be adjusted at acidic range. More-
over, Ca2+can play a role in dopamine conversion to AC,
which has a distinctive role in neurodegenerative process
of dopaminergic system. In summary, it would be pos-
sible that Ca2+ accelerates HHMA degradation or plays
a role in producing neurodegenerative diseases asso-
ciated with dopamine or MDMA neurotoxicity.
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